01-2 – Dominik Mumberg – The road to targeted therapies (Part 2)
1 Important Signal Transduction Pathways 2 Overview 3 FDA Approvals of Anti-Cancer Agents 4 HER Receptor Family 5 EGFR targeting antibodies and kinase inhibitors 6 Treatment-relevant mutations of EGFR in NSCLC 7 Approved Drugs against HER1 and HER2 8 Mechanisms of resistance to EGFR inhibitors 9 Targets synergistic to HER receptors 10 Drug candidates to PI3K, mTOR and MAPK 11 HIF-mediated signal transduction 12 Mitotic regulators as cancer targets 13 Conclusions — Targeted drugs 14 Do we simply need better cancer drugs? 15 Targeted application — definition 16 PI3-Kinase dependent signal pathways 17 Small molecule targeted drugs — context 18 Targeted antibodies — context 19 Conclusions — Targeted Applications
Video Rating: 0 / 5
JVZoo Product Feed
Targeted Delivery of Drugs to Brain Tumors
Trudy Forte of Berkeley Lab’s Life Sciences Division will discuss her work developing nano-sized low-density lipoprotein (LDL) particles that can be used as a safe and effective means of delivering anticancer drugs to brain tumors, particularly glioblastoma multiforme. This is the most common malignant brain tumor in adults and one of the deadliest forms of cancer. Her research team found that the synthetic LDL particles can target and kill such tumors cells in vitro. The nanoparticles are composed of a lipid core surrounded by a peptide. The peptide contains an amino acid sequence that recognizes the LDL receptor, and the lipid core has the ability to accumulate anti-cancer drugs. Her talk was presented June 27, 2007.
JVZoo Product Feed
Interrogating Circulating Tumor Cells to Direct Targeted Cancer Therapies
Air date: Wednesday, May 26, 2010, 3:00:00 PM Timedisplayed is Eastern Time, Washington DC Local Category: Wednesday Afternoon Lectures Description: Dr. Haber will present the development and characterization of a microfluidic device for the efficient capture of circulating tumor cells (CTCs) from blood specimens of patients with cancer. These cells represent potential biomarkers with which to follow disease progression, as well as providing important biological information into the process of metastasis. Examples will be provided, including the monitoring of tumor genotypes in EGFR-mutant lung cancer, as well as the molecular characterization of CTCs from patients with localized and metastastic prostate cancer. His laboratory interests have focused on the area of cancer genetics, including the etiology of the pediatric kidney cancer Wilms tumor and genetic predisposition to breast cancer. Recently, his laboratory reported that lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are uniquely sensitive to tyrosine kinase inhibitors that target this receptor. This observation has had important implications for the genotype-directed treatment of non-small cell lung cancer, and more broadly for strategies to identify critical genetic lesions in cancers that may serve as an “Achilles heel” and be suitable for molecular targeting. In collaboration with Dr. Mehmet Toner’s laboratory, Dr. Haber’s laboratory has recently established the …
JVZoo Product Feed
Categories: Videos Tags: targeted, therapies, cells, direct, tumor, cancer, interrogating, circulating
IASLC: Targeted Agent Slows Lung CA Symptoms
www.medpagetoday.com SAN FRANCISCO — The oral targeted agent vandetanib appears to slow progression of symptoms of advanced non-small cell lung cancer — a meaningful endpoint for patients — but did not improve overall survival researchers found.
Video Rating: 0 / 5
JVZoo Product Feed
Outsmarting Cancer – Targeted Drugs Fight Lung Cancer in North Shore Patient
When Wilmington resident Joan O’Beirne, 68, started experiencing shortness of breath during her daily activities, she had no idea what could be causing it or that she was about to become part of a pioneering research study. A widow with three grown children, O’Beirne has always been active and healthy, never smoking, playing tennis, and more recently watching her grandchildren every afternoon. When she noticed her shortness of breath, she consulted her primary care doctor who sent her to a lung specialist. Her early tests were inconclusive; she showed no sign of chronic obstructive pulmonary disease. Seeking an answer, O’Beirne’s doctors ordered additional testing for cardiac disease and blood clots as well as a CT scan of her lungs. Finally, the CT showed scar tissue in the upper left lobe of her lung that a radiologist suspected might be a sign of cancer. A PET scan confirmed active cancer cells and she was sent to a lung surgeon for a biopsy to determine the extent of her cancer. After a surgeon advised that her tumor would require a surgical biopsy—a procedure that increased the possibility of spreading the cancer—O’Beirne sought a second opinion. She consulted Massachusetts General Hospital and North Shore Medical Center thoracic surgeon and lung specialist, Dean Donahue, MD “Dr. Donahue assured me that he and the interventional radiologist could reach the tumor through a needle biopsy.” said O’Beirne. “I felt much safer with Dr. Donahue and his team.” O’Beirne’s …
Video Rating: 0 / 5
JVZoo Product Feed
Combining Targeted Therapies to ER+ Metastatic Breast Cancer: The Addition of mTOR Inhibitor
Part 3 of 3 – St. Gallen 2011: Targeted Therapies in Breast Cancer – Piecing Together Ways to Improve Patient’s Outcomes – Dr. Thomas Bachelot St. Gallen March 2011- Satellite symposium. The approaches to, and options for, the management of breast cancer are continually evolving. This is part 3 of 3 – Dr. Thomas Bachelot discusses “Combining Targeted Therapies to ER+ MBC: The Addition of mTOR Inhibitor”.
Video Rating: 0 / 5
JVZoo Product Feed
Categories: Videos Tags: breast, mtor, combining, metastatic, targeted, therapies, addition, inhibitor, cancer
Mixed Results for Mesothelioma From Targeted Therapies
Mixed Results for Mesothelioma From Targeted Therapies
Article by Agatha Simona
A review of recent clinical trials on various targeted therapies for malignant mesothelioma indicates that, while some are helpful, none are likely to become standard treatments yet.
In an article in the international journal Cancer Chemotherapy and Pharmacology, a pair of Danish researchers reported their analysis of 32 clinical trials on 17 different targeted agents for mesothelioma. A targeted agent is a medication that takes aim at a specific cellular function within mesothelioma tumor cells. Some inhibit proteins needed for growth or replication. Others may attack the formation of blood vessels or other structures that feed the cancer cells.
The extensive look at clinical trials of these targeted agents found that, overall, those that were used as a first-line treatment for mesothelioma induced responses ranging from 0 to 14%. Those that were used as a second-line treatment, after another therapy had already been tried, induced a 0 to 16% response. One of the more effective targeted agents appears to be sunitinib (brand name Sutent), a tyrosine kinase inhibitor that triggered some tumor shrinkage in 10% of mesothelioma patients, but resulted in ‘stable disease’ for 66% of them when used as a second-line treatment.
Another potentially effective targeted agent for some mesothelioma patients is bevacizumab (brand name Avastin). Bevacizumab is a monoclonal antibody and the first FDA-approved therapy designed to inhibit angiogenesis, the process by which new blood vessels form to support cancer cells. Primarily used for the treatment of metastatic colorectal cancer, recurrent metastatic non-squamous non-small cell lung cancer, and metastatic renal cell carcinoma, it is being tested as an addition to chemotherapy for mesothelioma patients.
As reported by the Danish researchers, some of the results of Avastin trials have been positive. When added to pemetrexed and cisplatin chemotherapy drugs, bevacizumab ‘significantly improved disease control in 73.5% of mesothelioma patients, compared to 43.2% who had chemotherapy alone. Bevacizumab did not appear to offer the same advantages when used along with another chemotherapy combination – gemcitabine and cisplatin. Unfortunately, other studies suggest that the drug may increase the risk of kidney damage.
The results of these mesothelioma trials prompted the authors of the meta-analysis to cautiously conclude, “Disease stabilization is reported in some patients with several targeted treatments and might be beneficial in subgroups of patients or in combination with classic chemotherapy.” They add, however, that none of the current targeted treatments available are effective enough to be recommended as standard treatment for malignant mesothelioma.
About the Author
Mesothelioma cancer patient resource with questions and answers about mesothelioma, a deadly cancer caused by asbestos exposure.
JVZoo Product Feed
ASCO 2009: Experimental targeted therapy improves progression-free survival for advanced NSCLC
Dr Roy Herbst, MD Anderson Cancer Center, Houston, US ASCO 2009: Experimental Targeted Therapy Vandetanib Improves Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer The results of an international trial have shown that adding the experimental targeted therapy vandetanib (Zactima) to docetaxel improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after first-line treatment. This is the first phase III study to show that adding a targeted therapy to second-line chemotherapy with docetaxel results in a clinical benefit for patients with advanced.
JVZoo Product Feed
Categories: Videos Tags: advanced, improves, survival, progressionfree, asco, targeted, therapy, 2009, nsclc, experimental
COPD targeted Combivent Inhaler from Canada Online
COPD targeted Combivent Inhaler from Canada Online
Article by Chani Prem T
COPD targeted Combivent Inhaler from Canada Online
Chronic obstructive pulmonary disease (COPD) causes wheezing and difficulty in breathing. This occurs due to the narrowing of the airway as a result of inflammation. The occurrence of COPD has increased due to increased pollution levels in the atmosphere. The WHO estimated that COPD is ranked the same as HIV/AIDS in the number of deaths associated with it. It is also stated that more than 3 million people dies of COPD worldwide. The Combivent inhaler is a relief medication which prevents wheezing and shortness of breath and other symptoms associated with chronic obstructive pulmonary disease. This medication is available with Canadian Online pharmacies at discounted rates.
What is COPD?
Chronic Obstructive Pulmonary Disease is a long term illness comprising of three conditions. These are chronic bronchitis, asthma and emphysema. Chronic bronchitis is an inflammation which occurs in the bronchial tubes with excessive secretions of mucus. This excessive secretion of mucus causes the tissues in the bronchial tubes to swell which in turn blocks the airway. Chronic asthma is similar to chronic bronchitis. However, asthma will only narrow the bronchial tubes without any mucus formation. Emphysema occurs when the alveolar wall in the lungs, as well, as the capillary blood vessels are destroyed over a length of time. When this occurs it limits the oxygen and carbon dioxide transfer. It also inflames and swells the airway. The most common cause for COPD is cigarette smoking and air pollution. Symptoms of COPD include chronic cough, shortness of breath, respiratory infections, and fever in the case of chronic bronchitis. Medical advice should be obtained to relieve symptoms of COPD. Early treatment during childhood years can reverse this condition while neglected COPD can lead to asthma in the long run.
What is Combivent used for?
When diagnosed with COPD, the symptoms of coughing and wheezing can be managed and reduced considerably with the use of an inhaler. Using the Combivent inhaler enables easy breathing as the active ingredients of Albuterol and Ipratropium work together to relax and open the airways which originally narrowed or inflamed due to COPD. Thus, the right dosage of this inhaler will prove to provide greatly needed relief from this illness. The dosage of Combivent is two inhalations that need to be taken four times a day. However, a doctor may prescribe an adjusted dosage depending on the severity of the condition. Combivent can be purchased from Bigmountaindrugs.com, which is, an accredited Canada pharmacy. Combivent can be purchased through them in its generic form as well as the branded form.
How to use the Inhaler?
Combivent comes in a metered-dose inhaler. This will deliver an amount of aerosol medication to the lungs which is inhaled. Before using it, the inhaler should be shaken vigorously and “test sprayed” 24 hours ahead to avoid any allergic reactions. The medication taken in the proper manner and inhaled deep into the lungs will provide relief rapidly. A single Combivent canister contains 200 sprays. This should be kept in mind as it will be difficult to detect if it is empty until too late. Keeping count will enable the user to purchase a new Combivent from any accredited Canadian Pharmacies online before running out altogether.
Adverse Effects of Combivent
Most medications have common side effects which may or may not be experienced by its user. Some of those who use Combivent may experience the side effects mentioned below.
Common Side Effects- coughing, dizziness, nausea, headache, dry mouth, sinus congestion etc.Severe Side Effects – fever, increased blood pressure, difficulty passing urine, allergic reactions, arrhythmia etc. If any severe side effects are experienced, it is important to be checked by a physician immediately.Although there are side effects, they will not outweigh the benefit of using the Combivent inhaler, which is relief in order to breathe properly. As narrowed airways can cause total airflow blockages in most severe cases, immediate treatment of wheezing symptoms is an essential.
About the Author
Author
Author Chani Muditha Thebuwana contributes articles related to drugs and illnesses courtesy of BigMountainDrugs.Com. You can buy Combivent Inhalers and other http://www.bigmountaindrugs.com/blog/ medications for COPD and asthma http://www.bigmountaindrugs.com/Buy_Abilify_5+mg from our online pharmacy, saving money and travel time to pharmacies. Visit Big Mountain Blog pages for information on health related issues.
COPD (bronchitis and emphysema) affects an estimated three million people in the UK, and smoking is a major cause. There is a lot that can be done to relieve the symptoms and improve your quality of life
More Copd Articles
JVZoo Product Feed
COPD Targeted Combivent Inhaler from Canada Online
COPD Targeted Combivent Inhaler from Canada Online
Article by Chani Prem T
COPD Targeted Combivent Inhaler from Canada Online
Chronic obstructive pulmonary disease (COPD) causes wheezing and difficulty in breathing. This occurs due to the narrowing of the airway as a result of inflammation. The occurrence of COPD has increased due to increased pollution levels in the atmosphere. The WHO estimated that COPD is ranked the same as HIV/AIDS in the number of deaths associated with it. It is also stated that more than 3 million people dies of COPD worldwide. The Combivent inhaler is a relief medication which prevents wheezing and shortness of breath and other symptoms associated with chronic obstructive pulmonary disease. This medication is available with Canadian Online pharmacies at discounted rates.
What is COPD?
Chronic Obstructive Pulmonary Disease is a long term illness comprising of three conditions. These are chronic bronchitis, asthma and emphysema. Chronic bronchitis is an inflammation which occurs in the bronchial tubes with excessive secretions of mucus. This excessive secretion of mucus causes the tissues in the bronchial tubes to swell which in turn blocks the airway. Chronic asthma is similar to chronic bronchitis. However, asthma will only narrow the bronchial tubes without any mucus formation. Emphysema occurs when the alveolar wall in the lungs, as well, as the capillary blood vessels are destroyed over a length of time. When this occurs it limits the oxygen and carbon dioxide transfer. It also inflames and swells the airway. The most common cause for COPD is cigarette smoking and air pollution. Symptoms of COPD include chronic cough, shortness of breath, respiratory infections, and fever in the case of chronic bronchitis. Medical advice should be obtained to relieve symptoms of COPD. Early treatment during childhood years can reverse this condition while neglected COPD can lead to asthma in the long run.
What is Combivent used for?
When diagnosed with COPD, the symptoms of coughing and wheezing can be managed and reduced considerably with the use of an inhaler. Using the Combivent inhaler enables easy breathing as the active ingredients of Albuterol and Ipratropium work together to relax and open the airways which originally narrowed or inflamed due to COPD. Thus, the right dosage of this inhaler will prove to provide greatly needed relief from this illness. The dosage of Combivent is two inhalations that need to be taken four times a day. However, a doctor may prescribe an adjusted dosage depending on the severity of the condition. Combivent can be purchased from Bigmountaindrugs.com, which is, an accredited Canada pharmacy. Combivent can be purchased through them in its generic form as well as the branded form.
How to use the Inhaler?
Combivent comes in a metered-dose inhaler. This will deliver an amount of aerosol medication to the lungs which is inhaled. Before using it, the inhaler should be shaken vigorously and “test sprayed” 24 hours ahead to avoid any allergic reactions. The medication taken in the proper manner and inhaled deep into the lungs will provide relief rapidly. A single Combivent canister contains 200 sprays. This should be kept in mind as it will be difficult to detect if it is empty until too late. Keeping count will enable the user to purchase a new Combivent from any accredited Canadian Pharmacies online before running out altogether.
Adverse Effects of Combivent
Most medications have common side effects which may or may not be experienced by its user. Some of those who use Combivent may experience the side effects mentioned below.
Common Side Effects- coughing, dizziness, nausea, headache, dry mouth, sinus congestion etc.Severe Side Effects - fever, increased blood pressure, difficulty passing urine, allergic reactions, arrhythmia etc. If any severe side effects are experienced, it is important to be checked by a physician immediately.
Although there are side effects, they will not outweigh the benefit of using the Combivent inhaler, which is relief in order to breathe properly. As narrowed airways can cause total airflow blockages in most severe cases, immediate treatment of wheezing symptoms is an essential.
About the Author
Author
Author Chani Muditha Thebuwana contributes articles related to drugs and illnesses courtesy of BigMountainDrugs.Com. You can buy Combivent Inhalers and other medications for COPD and asthma from our online pharmacy, saving money and travel time to pharmacies. Visit Big Mountain Blog pages for information on health related issues.
JVZoo Product Feed
Met Inhibitors: Targeted therapies for multiple cancers
Met Inhibitors: Targeted therapies for multiple cancers
Article by Katewinslet
INTRODUCTION
Mesenchymal-epithelial transition (Met) tyrosine kinase is the receptor for hepatocyte growth factor (HGF), which is normally active in wound healing, liver regeneration, and embryonic development. However, the Met pathway is one of the most frequently dysregulated pathways in human cancer. Met dysregulation leads to constitutive activation of its tyrosine kinase activity thus increasing the downstream signals that lead to cell survival, proliferation, and migration. Patients with upregulated Met tend to have aggressive, chemo-resistant cancers and poor prognoses. For these reasons, the pharmaceutical industry has expended much time and effort to identify potential Met tyrosine kinase inhibitors as potential therapeutics for these cancers.
POTENTIAL THERAPEUTICS
CrizotinibThe drug Crizotinib has been discussed previously in its role as an EML4-ALK inhibitor for treating non-small cell lung carcinoma. However, Crizotinib is also a Met-inhibitor and shows promise in several other forms of histological cancer associated with Met-dysregulation.
ForetinibForetinib is an inhibitor of both Met and vascular endothelial growth factor receptor (VEGFR). Foretinib completed Phase I clinical trials in 2010 and showed potential in treating aggressive solid tumors. Phase II clinical trials are currently underway testing its efficacy in both lung and breast cancer.
CabozantinibLike foretinib, Cabozantinib inhibits both Met and VEGFR. It was granted orphan drug status by the FDA in 2011. The orphan drug status is available to encourage pharmaceutical companies to develop drugs for diseases, known as orphan diseases, which have a small market because they are relatively rare. Orphan drugs proceed through their development along the same regulatory pathways as other drugs with the exception that some statistical burdens may be lessened in recognition of the limited patient pool. Furthermore, other financial incentives are also linked to orphan drugs such as tax incentives and extended patent protection. These exceptions are in place to encourage the pharmaceutical industry to develop drugs for these rare diseases, which, by definition, would have a small market share and be relatively unprofitable.
Cabozanitib is currently in clinical trials for treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular, kidney, and medullary thyroid cancer.
SUMMARY
The Met tyrosine kinase is one of the most dysregulated pathways in many cancers. The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit in multiple types of cancer. Therefore, for more than two decades, investigators have been exploring Met inhibitors as potential cancer treatments. Three drugs currently in development are crizotinib, foretinib, and cabozantinib, all of which are currently in early phase clinical trials for treatment of several different cancers. Met inhibitors may prove to be a targeted type therapy with reduced toxicity, that are effective at halting metastasis and improving prognosis in many types of previously resistant tumors.
REFERENCES
1. Porter, J (February 2010), “Small molecule c-Met kinase inhibitors: a review of recent patents”, Expert opinion on therapeutic patents 20 (2): 159-177,2. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang XY, Ruslim L, Blake R, Lipson KE, Ramphal J, Do S, Cui JRJ, Cherrington JM, Mendel DB (November 2003), “A selective small molecule inhibitor of c-Met kinase inhibits c-Met dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo”, Cancer Research 63 (21): 7345-55,3. Underiner TL, Herbertz T, Miknyoczki SJ (January 2010), “Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates”, Anti-cancer Agents in Medicinal Chemistry 10 (1): 7-27,4. Sattler M, Salgia R (April 2009), “The Met axis as a therapeutic target”, Update on Cancer Therapeutics 3 (3): 109-118,5. Christensen JG, Burrows J, Salgia R. (July 2005), “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention”, Cancer Letters 225 (1): 1-26,6. Qian, F; Engst, S; Yamaguchi, K; Yu, P; Won, KA; Mock, L; Lou, T; Tan, J et al. (2009). “Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases”. Cancer research 69 (20): 8009-16.7. Illingworth, Patricia; Cohen, Jillian (2004). “Orphan Drug Policies: Implications for the United States, Canada, and Developing Countries”. Health Law Journal 12: 183.
RELATED POSTS
Three tyrosine kinase inhibitors being used to treat chemo-resistant non-small cell lung carcinoma
VEGFR tyrosine kinase inhibitors effective in treating chemo-resistant renal cell carcinomaRelated to Met Inhibitors: Targeted therapies for multiple cancers
Three tyrosine kinase inhibitors being used to treat chemo-resistant non-small cell lung carcinoma
INTRODUCTION Lung cancer is the number one cause of cancer-related death worldwide. The two classes of lung cancer are small cell lung carcinoma (SCLC) and … EGFR(HER) inhibitors greatly improve prognosis for lung and pancreatic cancer
INTRODUCTION Lung cancer is the second most frequent cause of death in the US and it is the most deadly type of cancer. Lung cancer … Development of OSI-906, a IGF-1R inhibitor, for reversal of acquired erlotinib resistance
INTRODUCTION Insulin-like growth factor-1 receptor (IGF-1R) is a transmembrane tyrosine kinase receptor for IGF-1 and IGF-2. The normal physiological function of IGF and IGFR is …
About the Author
We pays great attention to the purity, stability and activity of the products like Compound Libraries, compound library, High Throughput Screening, Screening Libraries, Screening Library & more. Not only could we provides the chemical test data, such as HNMR, LC-MS and HPLC, but also provides the reviews overall evaluations of the products from the customers who have used our products. Western Blot, MTT, RT-PCR, ICH photos or figures provide a double guarantee for the biological activities of our products in life-science research.
JVZoo Product Feed
AACR 2011: New Phase I targeted cancer drugs.
Dr Lori Friedman – Genentech, California, USA Dr Lori Friedman, director of cancer signalling and translational oncology at Genentech, speaks about a session at the 2011 AACR congress where a number of previously undisclosed drugs in Stage I clinical trials were presented. The first drug discussed was a molecule which targets FGFR1, FGFR2 and FGFR3 in order to combat gastric and haematological malignancies. The second is a highly specific small molecule to target HER2. This drug is particularly exciting as it is able to cross from the blood into the brain. Due to this property it may be useful in treatment of HER2 positive breast cancer that has metastasised into the brain. Finally Dr Friedman talks about a drug which targets the ALK gene responsible for a subset of non-small lung cancer. Pfizer have previously developed a first generation drug to target both c-MET and ALK but this second generation drug is more specific and targets only ALK.
Video Rating: 5 / 5
JVZoo Product Feed
Lung Cancer at the Advent of Targeted Therapy – Milestones in Oncology
A dialogue with Dr. Thomas Lynch, Dr. Mario Lacouture, and Dr. Bruce Chabner With the development of new targeted drugs that exploit differences in gene expression between malignant and normal cells, conventional treatment of non-small cell lung cancer is undergoing a renaissance. To explore the impacts of contemporary drugs on lung cancer and to describe some of their side effects in patients, we are pleased to introduce two innovators who are at the leading edge of this Milestone in Oncology. “Lung Cancer … at the advent of targeted therapy,” is the topic that our interlocutor Dr. Bruce Chabner will discuss with Dr. Tom Lynch, a clinical investigator whose research is lengthening high quality life for lung cancer patients. We are doubly fortunate to also welcome Dr. Mario Lacouture whose research focuses on the dermatological disorders that arise in cancer patients as a consequence of some therapy.
Video Rating: 5 / 5
JVZoo Product Feed
Understand targeted therapy for lung cancer video
In this video from the National Comprehensive Cancer Network (NCCN), lung cancer expert Gregory Otterson, MD, of Ohio State University Comprehensive Cancer Center, gives lung cancer patients important information on targeted therapy for lung cancer (Tarceva or erlotinib) works. The NCCN is a not-for-profit alliance of 21 leading cancer centers—including Ohio State University Comprehensive Cancer Center—dedicated to improving care for cancer patients. For more free information to help you understand cancer and cancer treatment, look for the NCCN Guidelines for Patients, available at www.NCCN.com.
Video Rating: 0 / 5
JVZoo Product Feed
Fibro houses targeted in asbestos probe
Unions and the Cancer Council have called for scrutiny to be applied to houses built with fibro in a push to rid Australia of asbestos by 2030.
SMART METERS IN OLD HOUSES HAVE ASBESTOS BACKING When dealing with Asbestos, the Safety of your family and others solely relies on how good is the Asbestos removalist and the Hygienist. Please ask us for free advice. PLEASE ASK US FOR A QUOTE TO REMOVE YOUR ASBESTOS, LARGE OR SMALL JOBS WELCOME. Corrective Services Pty Ltd ACN: 121-241-674 | ABN: 75-121-241-674 Asbestos Removalist Lic: H06/01710 Mobile: 0415-743-036 Phone: 03-9018-5656 Office: 03 9221 6148 Local call: 1300-437-005 Fax: 03-5258-4067, victoriademolition.com www.asbestoscleanaway.com.au www.asbestosremovalvictoria.com.au Office Address: Level 27 -101 Collins St, Melbourne, 3000 Postal Address:128 Fellows Road, Point Lonsdale, Victoria 3225 Email: asbestos_services@me.com
JVZoo Product Feed
Physicians Are Closer To Targeted Patient Care with Biomarker Test
Physicians Are Closer To Targeted Patient Care with Biomarker Test
Article by Nichole Fowler
The researchers at the Asbestos Disease Research Institute (ADRI) discovered a marker in the blood of mesothelioma patients that shows the aggressiveness of the disease. The rates of tumor cell growth can differ significantly patient-to-patient so the best method of treatment for one patient may not yield optimal results in another patient. This new biomarker test will allow physicians to personalize treatment plans, catering to each patient’s condition.
The biomarker test is a biological molecule that is found in the patient’s blood, tissues or other body fluids that indicates the presence or absence of a particular disease/condition, as well as its level of aggressiveness as far as cancer cell growth. Biomarker tests are useful in diagnosing and determining the treatment of mesothelioma. Researchers have been spending an immense amount of time and money in researching ways to improve the diagnosis and treatment of mesothelioma. Researchers also hope their efforts will improve mesothelioma patients’ survival rates through their ability to personalize treatment plans.
Providing mesothelioma patients with personalized treatment can optimize the potential for a successful remission. Mesothelioma treatments often differ dramatically in type and dosage. Biomarker tests determine the patient’s level of disease aggressiveness and can open doors to treatment methods that were not considered before or would have been considered otherwise.
ADRI’s research on the biomarker test was led by Professor Nico van Zandwijk who believed that this new approach may spare patients who have advanced mesothelioma and a poor prognosis from having to undergo useless chemotherapy or radical surgery. This saves patients not only a lot of time and money, but also a lot of energy.Mesothelioma researchers and attorneys are providing patients not only with medical options, but also legal guidance to ensure their rights are protected. Majority of the patients diagnosed with mesothelioma were exposed to asbestos either in the workplace or secondhand through the clothing of a loved one who did work around asbestos.
About the Author
Mesothelioma Lawyer Profiles and Settlements.
JVZoo Product Feed
Marsh Targeted In Lloyd’s Suit.(Marsh & McLennan Cos.)(Statistical Data Included): An article from: National Underwriter Property & Casualty-Risk & Benefits Management Reviews
Marsh Targeted In Lloyd’s Suit.(Marsh & McLennan Cos.)(Statistical Data Included): An article from: National Underwriter Property & Casualty-Risk & Benefits Management
This digital document is an article from National Underwriter Property & Casualty-Risk & Benefits Management, published by The National Underwriter Company on June 4, 2001. The length of the article is 1169 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Marsh Targeted In Lloyd’s Suit
List Price: $ 5.95
Price: $ 5.95
[wprebay kw="asbestos+suit" num="0" ebcat="-1"] [wprebay kw="asbestos+suit" num="1" ebcat="-1"]
Find More Asbestos Suit Products
JVZoo Product Feed
Categories: Products Tags: underwriter, article, data, reviews, national, casualtyrisk, mclennan, management, cos.statistical, suit.marsh
Benefit of targeted lung cancer therapy confirmed
Benefit of targeted lung cancer therapy confirmed
( University of Colorado Denver ) A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of …
Read more on EurekAlert!
Prostate Cancer Foundation Funds .2 Million in New Creativity Awards for Advanced Research
The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.
Read more on Business Wire via Yahoo! Finance
Winthrop’s 7th Annual Cancer Center For Kids Golf Outing
When a child is diagnosed with cancer, treating the disease is only part of the battle. There are also a host of psychological, social and educational concerns for the child – and the child’s family. read more
Read more on Garden City News
JVZoo Product Feed
Targeted Cancer Therapy Reviews
Targeted Cancer Therapy
Price: $ 9.99
Winning the Battle Against Prostate Cancer
Price: $ 9.99
More Information On Cancers Products
JVZoo Product Feed
Targeted Therapy- A New Way of Treating Mesothelioma
Targeted Therapy- A New Way of Treating Mesothelioma
Article by Bello Kamorudeen
Conventional Mesothelioma cancer treatment consists mainly of three main options- surgery, chemotherapy, or radiation.
Newer medical therapies that are been discovered include the use of more targeted therapies that address the biological factors triggering mesothelioma growth might be a much more precise and effective way to combat this notoriously difficult cancer.
Mesothelioma is so difficult to treat properly because most often by the time it is diagnosed it is already in an advanced stage, and because it can take many biological forms. Current mesothelioma treatments were originally designed for other types of cancers, without considering factors that may be specific to mesothelioma. That may be why many patients only partially respond to treatment, and the average survival is just 12 months after diagnosis.
More specific “targeted therapies” that address the mechanisms that drive disease progression may actually provide a better means of prolonging the average life span of mesothelioma patients. “The term ‘targeted therapy’ refers to a new generation of anti-cancer drugs designed to interfere with a specific molecular ‘target,’ most often a protein or a receptor that is believed to have a critical role in tumor growth,” says lead study author Katalin Dobra, MD, PhD, a researcher in the Department of Laboratory Medicine at the Karolinska Institutet in Stockholm, Sweden.
“Targeted cancer therapy takes advantage of our recent knowledge of the key mechanism that the malignant [cancerous] cell needs for its survival, and uses the special properties of mesothelioma cells to design novel therapeutic strategies,” Dr. Dobra says.
The process starts with molecular screening to identify the characteristics of a tumor and how it behaves, what causes it to grow and spread. Then researchers test various therapies on cells in the laboratory to see if they can interfere with that process. Not until then can a new cure be tested on patients in clinical trials.
So far, Dr. Dobra’s team has identified three possible molecular targets, each with its own potential treatment:
* Proteasome-subunits are groups of enzymes that regulate cell progression and death. Potential treatment: Drugs called proteasome inhibitors have been shown to halt the growth of mesothelioma cells.
* The thioredoxin system contains components that are produced differently in cancerous and noncancerous mesothelial cells, and it is thought to contribute to the survival of mesothelioma cells. Potential treatment: In collaboration with other groups, Dr. Dobra has shown that the mineral selenite may trigger mesothelioma cell death while sparing healthy cells.
* Proteoglycans (PGs) are a class of proteins that differ based on the type of mesothelioma cell. They work by affecting the growth factors that help mesothelioma cells grow and divide. Potential treatment: Oligosaccharide sequences, which are made up of chains of sugar molecules, might interfere with the work of PGs.
One of these targeted approaches, proteasome inhibitors, is now being tested in clinical trials. The other two methods are also promising, but more research is needed before they can be tested on patients. Additional tumor targets are also being investigated.
The next step in the research is to combine various treatments-both traditional and experimental-to see which ones are most effective at targeting mesothelioma tumors, Dr. Dobra says. Attacking the tumors from as many different approaches as possible may offer the greatest benefit to mesothelioma patients.
About the Author
Bello kamorudeen. For more information on mesothelioma visit http://www.mesotheliomacorner.blogspot.com
More Treat Mesothelioma Articles
JVZoo Product Feed
Categories: Articles Tags: therapy, mesothelioma , treating, targeted
